CD8A and neoplasm: In addition, we followed-up the ICIs in blood: tumor-free and tumor-bearing animals which received LmAIO+α-PD-1 therapy demonstrated a predominantly low level of ICIs, whereas all other groups demonstrated elevated levels of ICIs on CD4/CD8 T cells (Supplementary Fig. S8G, H).